Recent studies showed promising effects of metformin in combination with glucagon-like peptide-1 (GLP-1) receptor agonists (16) and dipeptidyl peptidase 4 (DPP-4) inhibitors (17, 18) for T2DM prevention. This evidence concerns the gene GCG and type 2 diabetes mellitus.